Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 76 to 100 of 335

Guidance and quality standards awaiting development
Title	Type
Domvanalimab with zimberelimab for untreated unresectable advanced gastric, gastro-oesophageal junction or oesophageal cancer [ID6606]	Technology appraisal guidance
Dorocubicel for treating haematological cancer when a suitable donor is unavailable for an allogeneic haematopoietic stem cell transplant [ID6521]	Technology appraisal guidance
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years [TSID12046]	Technology appraisal guidance
Dulaglutide for treating type 2 diabetes [ID1451]	Technology appraisal guidance
Dupilumab for treating bullous pemphigoid [ID6479]	Technology appraisal guidance
Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years [ID6492]	Technology appraisal guidance
Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma [TSID10736]	Technology appraisal guidance
Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206]	Technology appraisal guidance
Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]	Technology appraisal guidance
Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours in people previously untreated with BCG [ID5080]	Technology appraisal guidance
Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944]	Technology appraisal guidance
Durvalumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6146]	Technology appraisal guidance
Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]	Technology appraisal guidance
Durvalumab with oleclumab or monalizumab for treating unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy [ID6626]	Technology appraisal guidance
Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428]	Technology appraisal guidance
Durvalumab with radiotherapy for treating unresected node-negative stage 1 or 2 non-small-cell lung cancer [ID6567]	Technology appraisal guidance
Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124]	Technology appraisal guidance
Durvalumab with tremelimumab and transarterial chemoembolisation with or without lenvatinib for treating locally advanced hepatocellular carcinoma PD [ID6527]	Technology appraisal guidance
Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]	Technology appraisal guidance
Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]	Technology appraisal guidance
Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]	Technology appraisal guidance
Edaravone for treating amyotrophic lateral sclerosis [TSID11869]	Technology appraisal guidance
Eflornithine with lomustine for treating anaplastic astrocytoma after radiotherapy and adjuvant temozolomide [TSID10046]	Technology appraisal guidance
Efzimfotase alfa for treating hypophosphatasia in people 2 years and over [TSID12257]	Technology appraisal guidance
Elamipretide for treating Barth syndrome in people of any age [ID6545]	Technology appraisal guidance

Results per page

10
25
50
All